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Myocarditis is an inflammatory disease of the heart muscle most commonly
caused by viral infection and often maintained by autoimmunity. Virus-induced tissue
damage triggers chemokine production and, subsequently, immune cell infiltration
with pro-inflammatory and pro-fibrotic cytokine production follows. In patients, the
overall inflammatory burden determines the disease outcome. Following the aim to
define specific molecules that drive both immunopathology and/or autoimmunity in
inflammatory heart disease, here we report on increased expression of colony stimulating
factor 1 (CSF-1) in patients with myocarditis. CSF-1 controls monocytes originating
from hematopoietic stem cells and subsequent progenitor stages. Both, monocytes
and macrophages are centrally involved in mediating tissue damage and fibrotic
scarring in the heart. CSF-1 influences monocytes via engagement of CSF-1 receptor,
and it is also produced by cells of the mononuclear phagocyte system themselves.
Based on this, we sought to modulate the virus-triggered inflammatory response in
an experimental model of Coxsackievirus B3-induced myocarditis by silencing the
CSF-1 axis in myeloid cells using nanoparticle-encapsulated siRNA. siCSF-1 inverted
virus-mediated immunopathology as reflected by lower troponin T levels, a reduction of
accumulating myeloid cells in heart tissue and improved cardiac function. Importantly,
pathogen control was maintained and the virus was efficiently cleared from heart tissue.
Since viral heart disease triggers heart-directed autoimmunity, in a second approach
we investigated the influence of CSF-1 upon manifestation of heart tissue inflammation
during experimental autoimmune myocarditis (EAM). EAM was induced in Balb/c mice
by immunization with a myocarditogenic myosin-heavy chain-derived peptide dissolved
in complete Freund’s adjuvant. siCSF-1 treatment initiated upon established disease
inhibited monocyte infiltration into heart tissue and this suppressed cardiac injury
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as reflected by diminished cardiac fibrosis and improved cardiac function at later
states. Mechanistically, we found that suppression of CSF-1 production arrested both
differentiation and maturation of monocytes and their precursors in the bone marrow.
In conclusion, during viral and autoimmune myocarditis silencing of the myeloid CSF-1
axis by nanoparticle-encapsulated siRNA is beneficial for preventing inflammatory tissue
damage in the heart and preserving cardiac function without compromising innate
immunity’s critical defense mechanisms.
Keywords: inflammation and immunmodulation, innate immunity, cytokines, monocytes/macrophages, RNA
interference, virus, infection-immunology, myocarditis
INTRODUCTION
Myocarditis and its sequela, dilated cardiomyopathy, are leading
causes of heart failure and sudden death in young adults
(1). While various agents may provoke cardiac inflammation,
viral infections are the most common trigger of myocardial
inflammation in the Western world. Although various viruses
are putative invaders of heart tissue, most of our knowledge on
disease pathology comes from infection with enteroviruses, in
particular CoxsackievirusB3 (CVB3). CVB3 had been reported
among the most prevalent pathogens causing viral myocarditis
in North America and Europe in the past (2, 3). Mouse
models using different strains with divergent susceptibility for
cardiotropic CVB3 elegantly reflect human disease with highly
diverse disease outcome (4, 5). The hereditary susceptibility
involves a certain immune-anchored genetic phenotype leading
either to altered virus control and/or to induction of deleterious
immunopathology (6–8). Severe virus-induced inflammation can
result in a subsequent loss of self-tolerance against cardiac
proteins, which contributes to additive auto-destructive activity
of infiltrating cells and exaggerates heart tissue damage (9, 10).
Cardiac myosin is such a crucial autoantigen in both human
and murine virus-induced myocarditis (9). Administration of
cardiac myosin or its pathogenic epitope in combination with an
adjuvant induces experimental autoimmune myocarditis (EAM)
in mice, a model that mimics certain aspects of myocarditis and
heart failure in humans (11).
Treatment options for patients with myocarditis are sparse
and both conventional immunosuppressive as well as anti-
viral approaches have not yielded the desired results in
clinical trials (12). Recent data suggest that it is not the
presence and/or replicative activity of invading viruses in the
myocardium that determines outcome, but the virus-triggered
abundance of infiltrating leukocytes is an independent risk
factor (13, 14). At the acute state of myocarditis in mice,
the majority of accumulating leukocytes in inflamed heart
tissue are CD11b+ monocytes and macrophages (15, 16).
Consistently, the presence of CD68+ macrophages is a diagnostic
hallmark for human myocarditis (3). Infiltration of immune
cells is cytokine/chemokine-dependent. Consistent with previous
findings (17), we have demonstrated that not CVB3-mediated
cytotoxicity itself, but the overwhelming cytokine response
initiated by viral PAMPs is responsible for disease severity. Lower
pro-inflammatory cytokine/chemokine production during the
early phase of infection paralleled in reduced inflammatory heart
tissue damage and protected mice from cardiac failure (14). As
monocytes and macrophages are key players that secrete pro-
inflammatory and pro-fibrotic cytokines thereby exacerbating
acute and chronic inflammatory injury during myocarditis
(4, 18), effector molecules that modulate their differentiation,
activity, and cytokine secretion might be putative drug targets for
myocarditis. We have previously described the precise targeting
of inflammatory monocytes and their precursors by optimized
lipid nanoparticles which were encapsulated with siRNA directed
against CCR2 or CD115 (19, 20). Injection of mice with these
nanoparticles resulted in rapid blood clearance, accumulation in
spleen and bone marrow, and localization to monocytes (19).
Here, we demonstrate RNA sequencing data obtained from
endomyocardial biopsies of patients with myocarditis indicating
a significantly increased production of Colony Stimulating Factor
1 (CSF-1). The development of monocytes depends on CSF-1
(21) and its receptor CSF-1R/CD115. CSF-1 can be expressed and
produced by various cells including monocytes themselves (22).
Local production of CSF-1 stimulates tissue-residentmacrophage
proliferation and reduces apoptosis, thereby influencing cellular
survival (23). CSF-1R is expressed on monocytes, macrophages,
dendritic cells and their precursors, including “granulocyte-
macrophage progenitors” (GMP), “monocyte-macrophage DC
progenitors” (MDP) and “common monocyte progenitors”
(cMoP) (24, 25). CSF-1 receptor signaling is a well-described
mechanism that leads to monocyte production from progenitors
and stimulates mature monocytes screwing them into a pro-
inflammatory state (26). Based on this, we hypothesized that
disruption of the CSF-1 axis in myeloid cells attenuates heart
muscle inflammation and the resulting organ damage during
myocarditis. Using mouse models of CVB3-induced myocarditis
and experimental autoimmune myocarditis, we have found that
silencing of CSF-1 upon treatment of mice with CSF-1 siRNA
encapsulated nanoparticles substantially mitigated inflammatory
heart muscle damage leading to less fibrosis formation and
improved heart muscle function without the risk of exacerbating
direct viral pathology.
MATERIALS AND METHODS
Study Approval
All subjects gave written informed consent in accordance with
the Declaration of Helsinki. The study protocol was approved
by the ethic committee of the Medical Faculty—University of
Heidelberg—project 390/2011 “Central biobank of Department
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Internal Medicine III for research on molecular and genetic
markers in patients with cardiovascular disease.”
RNA-Seq Analysis, Read Processing and
Mapping
Patient enrollment and biomaterial processing for RNA-seq
analysis of heart biopsies was performed as previously described
(27). In detail, biopsy specimens were obtained from the apical
part of the free LV wall during cardiac catheterization using
a standardized protocol. Biopsies of 1- to 2-mm diameter
were immediately washed in ice-cold saline (0.9% NaCl),
transferred and stored in liquid nitrogen until RNA extraction.
After diagnostic workup of the biopsies (histopathology), the
remaining material was used to isolate RNA with an Allprep Kit
(Qiagen). RNA purity and concentration were determined using
the Bioanalyzer 2100 (Agilent Technologies) with a Eukaryote
Total RNA Pico assay for RNA from biopsies. Sequencing
libraries were generated using the TruSeq Stranded Total RNA
Sample Preparation Kit with Ribo-Zero Human/Mouse/Rat from
Illumina, adhering to the standard protocol of the kit. Sequencing
was performed using 2 × 75 bp paired end sequencing on an
Illumina HiSeq2000 instrument. For transcriptome analysis, raw
read files were mapped with STAR v2.4.1c5 using GRCh37/hg19
and the Gencode 19 gene model (http://www.gencodegenes.
org/). Read counts were generated with help of subread’s feature
counts program 6 (subread version 1.4.6.p1), using uniquely
mapped reads only (28). Normalization was performed with help
of rlog-normalization (29). RNA seq data were deposited to the
public repository Gene Expression Omnibus (GEO) - NCBI,
accession number GSE120567. RNA seq data for DCM patients
are partially demonstrated in (30).
Differential Gene Expression- and Gene
Set Enrichment Analysis
Differential gene expression analysis of RNA-seq data was carried
out within the RStudio framework using the edgeR package (31).
Gene set enrichment analysis was performed with KEGG gene
sets.
Histology and Immunohistochemistry
Human endomyocardial biopsy tissue and murine tissue was
stained as described elsewhere (32). For AVM, paraffin embedded
organ tissue sections were stained with hematoxylin/eosin
(HE) or Masson’s trichrome according to standard protocols.
Immunohistochemical stains for CSF-1 (rabbit polyclonal,
abcam), T lymphocytes (CD3 and CD4) and mononuclear
phagocytes (Mac-3) was performed as previously described
(32). For EAM, hearts were excised 30 days after primary
immunization. Hearts were rinsed in PBS, fixed in 10% formaline
for 24 h and embedded in paraffin. Serial 5µm sections were
stained with Masson’s trichrome staining to quantify fibrotic
tissue formation. Severity of EAM was evaluated according to a
6-tier scoring system as previously described (19, 20). All slides
were counterstained with hematoxylin. Sections were mounted
with Pertex mounting media (Medite). Slides were viewed with a
Zeiss Axioskop 40 microscope.
Candidate Identification of CSF-1 siRNA
Lysates of several murine cell lines were tested on CSF1
expression. NIH-3T3 cells showed high CSF1 expression,
are readily to be transfected, and were therefore used in
candidate identification experiments. siRNA loaded lipid-based
nanoparticles were generated by Axolabs GmbH (Kulmbach,
Germany) as previously described (19). siRNA targeting CSF-
1 receptor (CSF-1R, CD115) is described elsewhere (33). To
generate siRNAs that target the CSF-1 transcript, NIH 3T3 cells
were transfected with siRNAs targeting CSF-1 or non-targeting
control siRNA complexed with Lipofectamine2000 Transfection
Reagent at 5 and 50 nM final concentration in quadruplicates.
Values for CSF-1 were normalized to GAPDH and related to the
mean value of three different control siRNAs (100% expression).
Optimal siRNA concentration yieldingmost efficient knockdown
of CSF-1 production was obtained with RNA transfections
starting at 100 nM in 6-fold dilution steps down to 10 fM.
CSF-1 siRNAs that showed the best knockdown in both the
dual concentration screen and the concentration response curve
screen were used for nanoparticle encapsulation and in vivo
experiments.
Induction of Acute Viral Myocarditis (AVM)
and Experimental Autoimmune Myocarditis
(EAM)
For induction of AVM, 5–7 weeks old male A.BY/SnJ mice
were infected intraperitoneally (i.p.) with 5 × 105 PFU
CVB3 (cardiotropic Nancy strain) provided by Klingel (15)
and Rahnefeld et al. (32). Original breeding stocks for
A.BY/SnJ mice were purchased from the Jackson Laboratory.
For EAM, male BALB/c were purchased from Janvier (Saint-
Berthevin, France). Myocarditis was induced by subcutaneous
injection of an emulsion containing 150 µg myosin peptide
SLKLMATLFSTYASAD (PSL GmbH, Heidelberg, Germany)
supplemented with complete Freund’s adjuvant (CFA) (Sigma-
Aldrich, Taufkirchen, Germany) and 5 mg/ml Mycobacterium
tuberculosis H37Ra (Sigma-Aldrich, Taufkirchen, Germany).
Directly after the initial immunization, mice were injected with
500 ng pertussis toxin (Sigma-Aldrich, Taufkirchen, Germany)
i.p. Seven days after the primary immunization, mice received
a second subcutaneous injection of 150 µg myosin peptide
supplemented with CFA and complemented withMycobacterium
tuberculosis. All mice were housed under standard laboratory
conditions with a 12-h light-dark cycle and access to water
and food ad libitum. For AVM, the protocol was approved by
the Committee on the Ethics of Animal Experiments of Berlin
State authorities [G0034/16]. EAM experimental protocols were
approved by the institutional review board of the University
of Heidelberg, Germany, and the responsible government
authority of Baden-Württemberg, Germany (project number
35-9185.81/G-209/12). All mouse studies were carried out in
accordance with the recommendations in the Guide for the Care
and Use of Laboratory Animals of the German animal welfare
act, which is based on the directive of the European parliament
and of the council on the protection of animals used for scientific
purposes. All efforts were made to minimize suffering.
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In vivo Silencing of CSF-1 During AVM and
EAM
The optimal CSF-1–targeted siRNA (siCSF-1) was scaled up for
in vivo studies. For viral myocarditis, mice were intravenously
treated with 0.5 mg/kg nanoparticle encapsulated siLUC or
siCSF-1 immediately prior to CVB3 infection and 2, 4, and 6 days
after infection. For EAM, nanoparticle treatment started 14 days
after the primary immunization with myosin peptide. Animals
received four i.v. injections of 0.5 mg/kg siCSF-1 or siLuciferase
(LUC)-nanoparticles (control siCD115) per week.
Evaluation of Knockdown Efficacy of
siCSF-1
Male BALB/c mice received single injections of 1.5 mg/kg lipid-
based nanoparticle containing either siLUC or siCSF-1 on three
consecutive days. Animals were sacrificed 24 h after the third
injection. Bone marrow cells were isolated and prepared for flow
cytometry-based sorting of monocytes, which were identified
as Lin−(CD90;B220;CD49b;NK1.1;Ly6G,Ter119);F4/80−;
CD11c−; CD11b+. Cell sorting was performed on a FACS
ARIAII (BD Bioscience, Heidelberg, Germany). RNA from
sorted cells was isolated using Trizol (Life Technologies,
Darmstadt, Germany). Knockdown efficacy was evaluated using
quantitative real-time PCR. Gene expression was normalized
to HPRT. The following primers were used: CSF-1: TCCCAT
ATGTCTCCTTCCATAAA (fwd), GGTGGAACTGCCAGT
ATAGAAAG (rev); CD115: CGAGGGAGATCTCAGCTACA
(fwd), GACTGGAGAAGCCACTGTCC (rev). HPRT: GTCAAC
GGGGGACATAAAAG (fwd), TGCATTGTTTTACCAGTG
TCAA (rev). For the AVM model, spleen tissue was isolated
8 days after virus inoculation and tissue homogenization was
performed using a lysis buffer containing 20mM HEPES, 1 %
(v/v) Triton X-100, 4mM EDTA, 1mM EGTA, 5mM TCEP,
50mM NaF, 5mM NaPP, 2mM Na-o-vanadate and Complete R©
protease inhibitor cocktail (Roche). Western blot analysis was
performed following standard procedures. After blocking with
5% milk/PBS-Tween at 4 ◦C overnight, membranes were probed
with the primary antibody α-CD115 (ab32633, Cell Signalling)
and α-actin (Merck Millipore). The bound primary antibodies
were detected using IRDye800CW labeled goat anti-mouse
secondary antibodies in conjunction with an Odyssey CLx
infrared imaging system (Li-Cor Biosciences, Bad Homburg,
Germany).
Echocardiography
Cardiac function and morphology of mice with AVM were
assessed with a VisualSonics Vevo 770 High-Frequency
Imaging System with the use of a high-resolution (RMV-
707B; 15–45 MHz) transducer during anesthesia with 1.5–2%
isoflurane. Temperature and ECG were continuously monitored.
For the EAM model, echocardiography was performed in
conscious animals on a VisualSonics Vevo 2100 30 days after
the first immunization. Standard imaging planes, M-mode,
and functional calculations were obtained. For AVM, the
parasternal long-axis four-chamber view of the left ventricle
(LV) was used to guide calculations of percentage fractional
shortening, ventricular dimensions and volumes. M-mode
echocardiographic images were recorded at the level of
the papillary muscles from the parasternal short-axis view.
An experienced reader blinded to treatment performed all
measurements. Ejection fraction (EF) and fractional shortening
(FS) were calculated based on M-mode measurements.
Flow Cytometry
Flow cytometric analysis was performed 8 days after infection
in AVM and 21 days after the first immunization in EAM.
Single cell suspension of bone marrow, spleen and heart tissue
were prepared as previously described (34). Hearts were flushed
with PBS and homogenized in RPMI 1,640 medium (Biochrom)
containing 10% (v/v) fetal calf serum (FCS) (Biochrom), 1% (v/v)
penicillin/streptomycin (Pan Biotech), 30mM HEPES, 0.1 %
(w/v) collagenase type 2 (Worthington) and 0.015% (w/v) DNase
I (Sigma-Aldrich) at 37◦C at 800 rpm for 30min. Afterwards,
10mM EDTA was added. Cells were washed with PBS and
passed through a 70µm cell strainer as described in reference
(35). For the identification of myeloid cells, cell suspensions
were stained with a cocktail of PE-conjugated anti-mouse
antibodies targeting hematopoietic lineage markers (B220 for B
cells (RA3-6B2, BD Bioscience), CD90.2 for T cells (53-2.1, BD
Bioscience), CD49b for NK cells (DX5, eBioscience), NK-T/NK
Cell Antigen for NK cells (U5A2-13, BD Bioscience) and Ter-119
for erythroid cells (TER-119, BD Bioscience)) and fluorescent-
dye conjugated antibodies against the following cell surface
markers: CD45.2 (104, Brilliant Violet 711TM, BioLegend), CD11b
(M1/70, PE-CF594, BD Bioscience), Ly6G (1A8, PerCP/Cy5.5,
BioLegend), Ly6C (HK1.4, Pacific BlueTM, BioLegend), CD11c
(N418, Brilliant Violet 510TM, BioLegend), I-A[b] (AF6-120.1,
FITC, BD Bioscience) and F4/80 (BM8, APC, BioLegend).
Cells were stained in PBS containing 2% FCS, 2mM EDTA
for 20min at 4◦C. For the identification of lymphoid cells,
cell suspensions were stained with fluorescent-dye conjugated
anti-mouse antibodies against CD45.2 (104, Brilliant Violet
711TM, BioLegend), CD3e (145-2C11, PerCP/Cy5.5, BioLegend),
CD4 (RM4-5, V500, BD Bioscience), CD8a (53-6.7, Pacific
BlueTM, BD Bioscience), B220 (RA3-6B2, FITC, BioLegend)
and CD19 (6D5, APC, BioLegend). The antibody staining
was followed by a cell viability stain (Fixable Viability Dye
eFluor R© 780, eBioscience) according to the manufacturer’s
protocol.
Monocytes were identified as Linlow
(CD90;B220;CD49b;NK1.1;Ly6G,Ter119), F4/80low, CD11clow,
CD11bhigh; or Fixable Viability Dyelow, CD45.2high, CD11bhigh,
(B220, CD90.2, CD49, NK-T/NK Cell Antigen, Ter-119)low,
Ly6Glow, SSClow, F4/80low and CD11clow and further
differentiated according to Ly6C-expression. Inflammatory
monocytes express high levels of Ly6C and patrolling monocytes
express low levels of Ly6C. Macrophages were identified
as Fixable Viability Dyelow, CD45.2high, CD11bhigh, Linlow,
Ly6Glow, SSClow, F4/80high and CD11clow/high. Dendritic
cells were identified as Fixable Viability Dyelow, CD45.2high,
CD11bhigh, Linlow, CD11chigh and MHC IIhigh (compared to
isotype control). Neutrophils were identified as Fixable Viability
Dyelow, CD45.2high, CD11bhigh, Linlow, Ly6Ghigh and SSChigh. B
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cells were gated as Fixable Viability Dyelow, CD45.2high, CD3low,
B220high and CD19high. T cells were gated as Fixable Viability
Dyelow, CD45.2high, B220low, CD3high and either CD4high or
CD8high. For identifying proliferating GMPs mice received two
s.c. injections of 1 mg/kg Bromdesoxyuridin (BrdU) 12 and 24 h
before the animals were sacrificed. BrdU was stained using BrdU
flow kit (BD Biosciences). Proliferating GMPs were identified as
(CD90;B220;CD49b;NK1.1;Ly6G;CD11b;CD11c;IL-7R;Sca-1)low
and (CD117;CD34;CD16/32;BrdU)high.
For the assessment of quantitative data, 123 count eBeads
(eBioscience) were used according to manufacturer’s protocol.
Data were acquired on a FACS Verse (BD Biosciences,
Heidelberg, Germany) or on a LSR II (BD Bioscience) and
analyzed with FlowJo v10.0 software (FLOWJO, Ashland,
United States). Reported cell numbers were normalized to the
weight of total hearts, yielding the number of respective cell
fraction per mg tissue.
Determination of Viral Load in Heart Tissue
Plaque assays were performed in triplicates on sub-confluent
green monkey kidney cell monolayers as described recently
(32). In situ hybridization of CVB3 RNA was performed
using probes generated with the DIGoxigenin (DIG) RNA
labeling kit (Roche) and the pCVB3-R1 plasmid. Plasmid
cDNA was linearized with SmaI (36); all other steps were
conducted as previously described (37). DIG-labeled CVB3
RNA was detected using a horseradish-peroxidase-conjugated
DIG antibody (Roche 1:100). HistoGreen (Linaris) was
used as a substrate. All slides were counterstained with
hematoxylin.
High-Sensitive (hs)-Troponint (TnT)
Blood was sampled by facial vein puncture and collected
in a heparinized capillary. Thereby obtained plasma
was diluted 1:15 in PBS. hs-TnT was determined by
the electrochemiluminescence method (ECLIA; Elecsys
2010 analyzer) according to the method described in
reference (38).
Statistics
Statistical analysis of the data was performed in GraphPad
Prism v6.00/v.700 for Windows (GraphPad Software, La Jolla,
California, United States). Logarithmic data (virus titer, semi-
quantitative RNA quantification) measured on a linear scale
was transformed logarithmically prior to data plotting and
data analysis. Data summary is indicated on plots as mean
± SD unless stated otherwise. Unpaired t-tests were used
for two group comparisons. If samples had unequal variances
(determined by an F-test), an unpaired t-test with Welch’s
correction was used. For multiple group comparison unequal
variance versions of ANOVA (1-way or 2-way ANOVA) were
performed followed by a Sidak-Holm’s multiple comparison
test. The significance threshold for all tests was set at the 0.05
level.
FIGURE 1 | Transcriptome analysis of endomyocardial specimen from patients with dilated cardiomyopathy and myocarditis. RNA-Sequencing data from
endomyocardial biopsies obtained from patients with clinically diagnosed myocarditis or dilated cardiomyopathy as a control were analyzed for relative expression of
different gene sets. (A) RNA-seq analyses revealed differential expression of 1963 genes. Heatmap depicts top 500 differentially expressed genes hierarchically
clustered by using Euclidean distance measures. (B) CSF-1 and CSF-1R expression taken from RNA-seq data. Unpaired t-tests were used; p-values are indicated on
the graph and significant differences (p < 0.05) are marked with blue color.
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RESULTS
Increased Abundance of CSF-1 in Heart
Muscle Tissue During
Myocarditis/Inflammatory Cardiomyopathy
RNA-seq analyses revealed that myocarditis results in a
diverse transcriptional response in the patient’s heart tissue.
We observed 1963 differentially expressed genes in biopsies
taken from patients with acute myocarditis vs. patients
with a non-inflammatory dilated cardiomyopathy (DCM)
(Figure 1A). Gene set enrichment analysis (GSEA) revealed that
a decent amount of differentially expressed genes participates
in inflammatory processes (especially cytokines and cytokine
receptors) and differentiation of hematopoietic cell lineages
(Table 1). Myocarditis leads to a massive infiltration with
immune cells into heart tissue. Monocytes represent the
most prominent leukocyte population both during virus-
mediated and experimental autoimmune myocarditis (16, 32).
Monocyte production and maturation is strongly dependent
on CSF-1 and CSF-1R, and, both effector molecules were
identified in two gene sets mentioned above. Our data
indicate a pronounced up-regulation particularly of CSF-
1 and CSF-1R in endomyocardial specimen from patients
with myocarditis/inflammatory cardiomyopathy (Figure 1B).
Immunohistochemical stain of heart tissue from patients
with myocarditis revealed CSF-1 expressing cells only within
inflammatory foci, with a strong focus on mononuclear
immune cells (Figure 2A). Altogether, these data argued toward
a significant contribution of monocytes/macrophages to the
cardiac CSF-1 expression, which we found in patients with
inflammatory heart disease.
Local production of CSF-1 stimulates tissue-resident
macrophage proliferation and reduces apoptosis (23). In
addition to this function and a direct role of CSF-1 during
monocyte development, it might also influence pro-fibrotic
processes under inflammatory conditions. Since inflammation
and fibrosis are hallmarks of inflammatory heart disease,
we aimed to investigate the pathophysiological influence of
CSF-1 with respect to manifestation of inflammatory heart
tissue injury. First, we determined CSF-1 production in a
mouse model of CVB3-induced myocarditis. We performed
immunohistochemical stains to evaluate CSF-1 abundance
during viral myocarditis. Consistent with our findings in
patients, CSF-1 production was increased within inflammatory
foci at the acute state of myocarditis in mice (Figure 2B). Since
monocytes/macrophages represent the major infiltrating cell
population in acute myocarditis, it is very likely that these
cells are also involved in CSF-1 production. By double labeling
immunohistochemistry we found CSF-1 protein expression in
a part of Mac-3 positive mononuclear phagocytes within the
cardiac inflammatory lesions (Figure 2C).
Nanoparticle-Encapsulated siRNA
Effectively Downregulates CSF-1
Production in Monocytes
CSF-1 can be expressed and produced by various cells including
monocytes themselves (22). siRNA encapsulated in lipid-based
nanoparticles has been shown to effectively downregulate target
genes in monocytes and their lineage progenitors (19, 20).
Furthermore, in vivo knockdown of CSF-1R and monocyte
depletion with nanoparticle-encapsulated siRNA has recently
been demonstrated for ischemic heart disease (33). Thus, in
order to investigate the pathophysiological function of CSF-1
production by monocytes/macrophages on inflammatory tissue
damage during myocarditis, we decided to use a nanoparticle-
encapsulated siRNA approach to target CSF-1 production in
myeloid cells. To identify siRNAs leading to highly efficacious
suppression of CSF-1 production, 24 different siRNAs targeting
CSF-1 were investigated regarding their influence on CSF-1
mRNA levels in vitro (Figure 3A). Six different siRNAs, which
yielded optimal in vitro suppression of CSF-1 mRNA production,
were further investigated for their knockdown efficacy. Next, we
screened the respective CSF-1 directed siRNA regarding to the
concentration-dependent knockdown efficacy (Figure 3B) and
selected the most efficacious siRNA for in vivo nanoparticle
studies. Naive BALB/c mice were intravenously inoculated with
TABLE 1 | Top 10 C2 curated gene sets (KEGG Database) significantly enriched in human biopsies.
Gene set name (KEGG database) Description p-value FDR q-value
CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION Cytokine-cytokine receptor interaction 2.11E−20 3.93E−18
SYSTEMIC_LUPUS_ERYTHEMATOSUS Systemic lupus erythematosus 5.61E−19 5.22E−17
CELL_ADHESION_MOLECULES_CAMS Cell adhesion molecules (CAMs) 1.3E−17 8.07E−16
HEMATOPOIETIC_CELL_LINEAGE Hematopoietic cell lineage 2.08E−15 9.67E−14
VIRAL_MYOCARDITIS Viral myocarditis 5.19E−14 1.93E−12
NEUROACTIVE_LIGAND_RECEPTOR_INTERACTION Neuroactive ligand-receptor interaction 2.81E−13 8.71E−12
LEISHMANIA_INFECTION Leishmania infection 4.67E−13 1.24E−11
COMPLEMENT_AND_COAGULATION_CASCADES Complement and coagulation cascades 2.62E−11 6.1E−10
RIBOSOME Ribosome 1.91E−10 3.96E−9
CHEMOKINE_SIGNALING_PATHWAY Chemokine signaling pathway 2.61E−10 4.64E−9
RNA-Sequencing data of endomyocardial biopsies from patients with clinically diagnosed myocarditis or dilated cardiomyopathy as a control were analyzed for relative expression of
different gene sets. Indicated are the names, description and p-values (with FDR-adjustment) of the most relevant gene sets.
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FIGURE 2 | CSF-1 production in cardiac tissue during viral myocarditis. Paraffin-embedded tissue sections from endomyocardial biopsies that had been obtained
from patients with acute myocarditis were stained by immunohistochemistry. (A) Representative micrographs stained with an anti-CSF-1 antibody [left column] or with
a secondary antibody only [right column] are depicted. top: scale bar = 120µm; bottom: scale bar = 60µm. (B) Heart tissue sections were obtained from
CVB3-infected A.BY/SnJ mice on day 8 p.i. Representative micrographs of anti-CSF-1 stained heart tissue are shown [scale bar = 36µm]. (C) In addition, cardiac
sections from mice were double-stained with an antibody directed against Mac-3 (red) [left: scale bar = 36µm; center: scale bar = 12µm] and against CSF-1 (green).
As control, Mac-3 stained tissue sections were counterstained omitting the anti-CSF-1 directed antibody [right: scale bar = 12µm].
1 mg/kg of this nanoparticle-encapsulated siRNA (termed siCSF-
1) on three consecutive days. Expression of CSF-1 was found
to be effectively downregulated in monocytes that were sorted
from spleen of siCSF-1 treated mice and further evaluated
by quantitative PCR analysis (Figure 3C). Since pathogens are
frequently involved in the pathogenesis of myocarditis (5), as
a next step we set up an experimental approach to decipher
the CSF-1 axis using nanoparticle-encapsulated siRNA in a
mouse model of virus-mediated myocarditis. A.BY/SnJ mice
with high hereditary susceptibility for the development of acute
viral myocarditis (AVM) were treated with siCSF-1 or respective
controls directly prior to infection with cardiotropic CVB3
(Nancy). siCSF-1 treatment was repeated every other day until
mice were sacrificed 8 days after infection at the respective peak
of infiltration in heart muscle (Figure 3D) (6–8). Following this
protocol, we monitored the abundance of CSF-1 receptor levels
in spleens of infected mice, which allowed us to conclude on
the efficiency of siCSF-1 treatment during infection. Consistent
with virus-mediated mobilization of monocytes/macrophages
from bone-marrow sources, viral infection resulted in increased
CSF-1R levels in the spleen. In siCSF-1-treated mice, we found
reduced CSF-1R levels being indicative of suppressedmyeloid cell
mobilization upon siCSF-1 injection during AVM (Figure 3E).
siRNA-Mediated Knockdown of CSF-1
Attenuates Virus-Mediated Pathology
Since we found reducedmobilization of monocytes/macrophages
in siCSF-1-treated mice during CVB3 infection, this mouse
model allowed us to delineate the pathophysiological role
of CSF-1 production particularly by monocytes/macrophages
during viral myocarditis. First, we questioned whether siCSF-
1 treatment manipulated the viral load during AVM. The viral
burden as reflected by the amount of infectious viral particles
(Figure 4A) was not substantially influenced by siCSF-1 in heart
tissue at the acute state of infection. Thus, targeting the CSF-
1 axis represents a safe approach regarding to control of virus
dissemination and replication in A.BY/SnJ mice. During virus-
mediated myocarditis, there is a strong spatial-temporal relation
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FIGURE 3 | Suppression of CSF-1 production by siRNA-encapsulated nanoparticles. (A) NIH-3T3 cells were transfected with 24 siRNA candidates directed against
CSF-1. siRNA #7 was most efficient to reduce CSF-1 mRNA expression both at 5 and 50 nM and was selected for further studies. (B) CSF-1-directed siRNA # 7 was
titrated and the respective CSF-1 knockdown efficacy was determined. (C) Knockdown efficacy of nanoparticle-encapsulated CSF-1 candidate siRNA pool 7 after
injection into naive Balb/c mice (n = 3). (D) A.BY/SnJ mice were intravenously treated with nanoparticle encapsulated siRNA targeting either luciferase (n = 7 siLUC,
gray color) or CSF-1 siRNA #7 (n = 8 siCSF-1, green color) directly prior to CVB3 inoculation. siRNA treatment was repeated after 2, 4, and 6 days. (E) The overall
efficacy of siCSF-1 treatment during AVM as indicated by the presence of CSF-1-R)-positive cells was monitored by Western blot analysis of spleen tissue
homogenates (n = 6 mice per group) 8 day after virus inoculation. CSF-1R (high molecular weight band) and the cytoplasmic domain of CSF-1R (around 55 kDa) are
depicted. Fluorescence was quantified by the Image Studio Lite Ver 5.2 software. Signal intensity was normalized to actin and is depicted as relative expression levels
compared to siLUC-treated mice in the bar graph. Unpaired t-tests were used; p-values are indicated on the graph and significant differences (p < 0.05) are marked
with blue color.
between virus-induced cellular injury and the emergence of
inflammatory foci in heart tissue (39). Likewise, viral genome
abundance as detected by CVB3 in situ hybridization was
spatially connected with high-grade inflammation and most
impressive in siLUC-treated mice (Figure 4B). Since CVB3 does
not only target the heart, but also replicates in the pancreas,
we also determined the magnitude of virus-induced pancreas
destruction and found similar tissue injury in both siLUC- and
siCSF-1-treated groups (Figure S1).
Next, CVB3-infected mice that received siCSF-1 or siLUC as a
control were followed for global signs of acute infection. siCSF-1
treatment profoundly attenuated overall virus-induced pathology
as represented by significantly less pronounced body weight
reduction (Figure 4C) and only a minor loss of body temperature
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FIGURE 4 | Depletion of CSF-1 attenuates virus-mediated pathology. Mice with AVM were subjected to CSF-1 siRNA treatment as indicated in Figure 3D.
(A) Infectious virus particles were determined in heart tissue homogenates by plaque assay. Data summary is mean ± SEM. A student‘s t-test was conducted and the
p-value is shown. (B) To localize viral RNA in infected heart tissue, in situ hybridization for the detection of the CVB3 genome was performed and slides were
counterstained with hematoxylin/eosin. Representative micrographs are depicted (scale bar = 60µm). During viral infection, mice were monitored for body weight
(C) and body temperature (D) at the indicated points in time. Dots represent mean ± SEM. Repeated measurements versions of two-way ANOVA were performed
followed by a Sidak- Holm multiple comparison procedure. P values are indicated (blue color indicates p < 0.05; only significant results are depicted on the graph).
(E) To assess injury of cardiomyocytes prior to peak of inflammation, blood was sampled 5 days after infection by facial vein puncture and high sensitive (hs) troponin T
plasma levels were determined. Obtained results were normalized to the results obtained with blood samples from non-infected siLUC-treated mice and are depicted
(Continued)
Frontiers in Immunology | www.frontiersin.org 9 October 2018 | Volume 9 | Article 2303
Meyer et al. CSF-1 Axis in Myocarditis
FIGURE 4 | as fold changes. Data summary is mean + SD. Repeated measurements two-way ANOVA was performed followed by a Sidak-Holm’s multiple
comparison test and the p value is depicted. (F) After sacrificing mice 8 days after infection, heart tissue sections were stained with hematoxylin/eosin. (G) To quantify
cell infiltration, single cell suspensions of heart tissue obtained from naive mice (uninfected mice that did not receive siRNA treatment; white bars, n = 4) as well as
AVM and siRNA-treated mice (siLUC: gray squares, n = 7; siCSF-1: green squares, n = 8) were stained with CD45 antibodies to quantify total leukocyte count in the
heart. (H) Cardiac function was assessed by echocardiography prior to CVB3 infection in A.BY/SnJ mice (baseline) by an experienced and blinded investigator. Mice
were allocated to respective groups: siLUC and siCSF-1. In all CVB3-infected mice, echocardiography was repeated 8 days after CVB3 infection (siLUC n = 16;
siCSF-1 n = 17 mice). Data were analyzed regarding putative alteration during AVM in the respective treatment groups (day 8 after infection vs. baseline
measurements of the same cohort). Relative changes of stroke volume, heart rate and cardiac output compared to baseline measurements were calculated for each
group and these fold changes are depicted for siLUC and siCSF-1-treated groups. One-sample t-tests were performed to compare baseline measurements and
values obtained 8 days after infection. All p values are depicted, p < 0.05 are in blue color.
during infection in comparison to controls that received siLUC
(Figure 4D). Overall diminution of virus-mediated pathology
under siCSF-1 influence was further corroborated by a significant
reduction of cardiac troponin T serum levels as a heart-
specific sign of tissue damage (Figure 4E). Cardiac troponin
T at an early state of myocarditis might reflect both direct
virus-induced cytotoxicity and tissue destruction by innate
mediators of the immune response. In line with this, analysis
of heart tissue obtained from siCSF-1 treated animals sacrificed
8 days p.i. revealed distinct differences. Histological staining of
heart tissue (Figure 4F) demonstrated a profound myocarditis
in siLUC-treated A.BY/SnJ mice and in contrast to that
only moderate signs of myocarditis after siCSF-1 treatment.
Since viral injury of cardiomyocytes provokes an inflammatory
response that significantly contributes to tissue damage and
functional impairment of the heart (32), next we quantified
infiltration with CD45+ immune cells into hearts from siCSF-
1 and siLUC-treated mice by flow cytometry. We found a
significant reduction of infiltrating leucocytes in siCSF-1 treated
mice (Figure 4G), thus indicating reduced inflammatory organ
damage under suppression of the CSF-1 axis. Following up on
observed systemic and heart-tissue specific responses to siCSF-1
treatment, siCSF-1 effects on cardiac performance were assessed
by echocardiography during the inflammatory peak of viral
myocarditis. In siLUC-treated, infected A.BY/SnJ mice, both the
stroke volume and cardiac output were significantly reduced in
comparison to baselinemeasurements (Figure 4H) andTable S1.
Consistent with its heart-directed effects, siCSF-1 treatment
mitigated these detrimental changes and CVB3 infection in
this group resulted only in minor, non-significant reduction of
cardiac performance (Table S1).
siRNA-Mediated Knockdown of CSF-1
Diminishes Immune Cell Infiltration During
Acute Viral Myocarditis
As a next step, we aimed to determine whether siCSF-1
specifically influenced infiltration with monocytes/macrophages
or whether other immune cells were affected as well.
Immunohistochemistry using antibodies directed against
marker proteins for myeloid (Mac3) and T cells (CD3
and CD4) indicated reduced infiltration of these respective
immune cell populations in siCSF-1-treated mice during
AVM (Figures 5A,B). These findings were corroborated by
the results obtained from a quantitative flow cytometry-based
analysis of the different immune cell populations in infected
mouse hearts. We detected 756 ± 63 CD11b+/lineage− cells
in siLUC- vs. 273.3 ± 30.8 CD11b+/lineage− cells/mg heart
tissue in siCSF-1 treated mice (p < 0.0001) and 198 ± 34 T
cells in siLUC- vs. 95 ± 12 T cells/mg heart tissue in siCSF-1
treated mice (p = 0.02; Figures 5C,E). The vast majority of
infiltrating myeloid cells belonged to the pool of inflammatory
monocytes (Figure 5D). Consistent with the influence of CSF-1
on monocyte recruitment and differentiation, inflammatory
monocytes were highly significantly reduced in infected mouse
hearts upon siCSF-1 treatment. siCSF-1 also led to a significant
reduction of patrolling monocytes, macrophages and dendritic
cells (Figure 5D), which might all originate from inflammatory
monocytes. In correspondence to previous reports (15), the pool
of invading T cells during AVM was majorly comprised of CD4+
T cells. Comparable to siCSF-1-induced effects on myeloid cell
infiltration, we also found a significant reduction of the CD4+ T
cell count in heart tissue upon siCSF-1-treatment (Figure 5E).
siRNA-Mediated Knockdown of CSF-1
Mitigates Inflammatory Heart Tissue
Damage in a Mouse Model of Experimental
Autoimmune Myocarditis
siCSF-1 treatment impressively improved cardiac function upon
mitigating the inflammatory damage response during acute
viral myocarditis. A high inflammatory disease burden at the
acute state might directly translate into the manifestation
of a chronic functional impairment. Long-term sequela of
acute myocarditis involve cardiac remodeling processes with
substantial fibrosis formation and a reduction of systolic cardiac
function (4). Experimental autoimmune myocarditis (EAM)
represents an excellent model that enables researchers to follow
inflammatory disease progression from acute to chronic states
of myocardial dysfunction (40). Therefore, we investigated the
pathophysiological role of CSF-1 also in EAM, and started
siCSF-1 treatment upon manifestation of myosin-heavy chain-
directed autoimmunity 14 days after the first immunization
(Figure 6). This application strategy might also be considered as
a therapeutic regime starting uponmanifestation of acute disease.
Similar to the AVM model, intravenous siCSF-1 nanoparticle
application was repeated every 48 h for a 1-week course. First,
we performed a quantitative flow cytometry-based analysis of
inflammatory monocytes in the injured hearts directly after this
siCSF-1 treatment period. As expected from our results obtained
in AVM, we indeed found a reduced number of inflammatory
Ly6Chigh monocytes in siCSF-1-treated animals compared to the
siLUC-treated controls during EAM (Figure 6B). To investigate
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FIGURE 5 | Influence of CSF-1 on immune cell infiltration into heart tissue during AVM. To further differentiate immune cell infiltration, immunohistochemical stain for
(A) mononuclear phagocytes using antibodies directed against Mac-3 and (B) T-cells using antibodies directed against CD3 and CD4 were performed (scale
(Continued)
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FIGURE 5 | bars = 60µm). Further differentiation by flow cytometry (Figure S2) was performed. (C) Total infiltrating myeloid cells (identified as CD45+, CD11b+,
lymphoid lineage− life single cells) were quantified. (D) Myeloid cells were further differentiated according to the gating strategy depicted in Figure S2A. (E) Equally,
lymphoid cells were further analyzed. Representative flow cytometry dot blots of siLUC- and siCSF-1-treated groups are depicted. Unpaired t-tests were performed
between siLUC- and siCSF-1-treated groups and p-values are shown. Significant differences (p < 0.05) are marked with blue color.
whether CSF-1 promotes monocyte development from bone-
marrow sources during EAM, we next evaluated the influence of
CSF-1 knockdown on granulocyte-monocyte progenitor (GMP)
cell numbers. siRNA-mediated knockdown of CSF-1 led to
markedly increased numbers of GMPs in the bone marrow
during EAM (Figure 6C). However, proliferation rates of GMPs
did not differ significantly between siLUC- and siCSF-1-treated
groups (Figure 6D). To further validate that CSF-1 knockdown
leads to an arrest of progenitor cells in the bone marrow, we
measured myeloid cell numbers in the blood and found reduced
numbers 21 days after EAM induction (Figure 6E).
Based on our finding of reduced infiltration with
inflammatory monocytes upon siCSF-1 treatment, next we
followed mice for a total of 30 days after EAM induction
and determined the formation of fibrotic scars as an integral
hallmark of cardiac remodeling at this chronic disease state
(Figure 7A). Knockdown of CSF-1 production resulted in a
significant reduction of fibrosis formation in the heart muscle
as indicated by quantitative assessment of Masson’s trichrome
stains (Figure 7B). Consistent with this reduction of long-
term, inflammation-mediated tissue damage in the siCSF-1
group, functional investigation of cardiac performance by
echocardiography revealed an improved ejection fraction in
siCSF-1-treated animals compared to siLUC-treated control
animals (Figure 7C). Chronic disease in siLUC-treated mice was
mirrored by a substantial reduction of cardiac contractility. As a
proof of principle, we also tested whether knockdown of CSF-1R
expression could exert similar effects during disease course.
Therefore, upon establishment of autoimmune myocarditis
mice were treated with a nanoparticle-encapsulated siRNA
that specifically targets CSF-1R (33). Formation of cardiac
fibrosis assessed 30 days after EAM induction was found to
be diminished in comparison to siLUC-treated controls, and
was reduced to similar levels as achieved by siCSF-1-treatment
(Figure 7B). Likewise, echocardiographic imaging of siCSF-
1R-treated animals demonstrated significant improvement of
cardiac performance as indicated by higher left ventricular
ejection fraction in comparison to siLUC nanoparticle-treated
animals (Figure 7C). Altogether, our data demonstrate that
silencing the CSF-1 axis hampers monocyte development and
substantially mitigates inflammatory heart tissue damage both in
a mouse model of viral and autoimmune-mediated myocarditis.
Moreover, initiation of CSF-1 knockdown upon manifestation
of inflammatory tissue damage attenuates the manifestation of
debilitating long-term sequela of acute inflammatory injury,
and this parallels in preserved systolic contractility of the heart
muscle (Figure 8).
DISCUSSION
One of the major causes of heart failure particularly in young
patients is myocarditis. Direct viral cytotoxicity stimulates
infiltration and immune response activation leading to pathogen
clearance and resolution of organ damage. Nevertheless, in
immune-genetically predisposed individuals there is also an
adverse scenario where pathogen-induced immune response
activation subsequently induces overwhelming inflammatory
cytokine response and detrimental immunopathology or
autoimmune processes, both leading to cardiac remodeling
and fibrotic scarring. It appears to be a slim line between the
induction of inflammation to fight the virus and exaggerated
immune responses that begin to be deleterious. We here
downregulated an important branch of the innate immunity—
the development of monocytes/macrophages—by siCSF-1
treatment for approximately a week during the acute phase of a
viral infection, yet found no impairment on pathogen control.
In fact, silencing CSF-1 production impressively mitigated
acute inflammatory heart tissue damage and attenuated the
development of a debilitating long-term sequela of acute
inflammatory injury to the heart. This nanoparticle-mediated
immune-modulation improved the course of disease both in
acute viral myocarditis and autoimmune inflammatory heart
disease and importantly, did not adversely influence viral burden
and clearance of infectious particles. As it might be hypothesized
that attenuating inflammatory activity could allow for enhanced
virus-induced cell death, this is not what we observed with
siCSF-1 treatment. Our finding is in line with previous data: out
of 46 studies that intervened the immune response, more than
90% found no adverse effect on viral load (4). In line with this, we
could recently demonstrate that inhibition of cellular proteolysis
in immune cells by the immunoproteasome inhibitor ONX 0914
is highly efficient to reverse high grade AVM and this protective
effect was attributed to maintained immune cell homeostasis,
but not to direct antiviral aspects (14).
A.BY/SnJ mice that were used in this study for AVM are
characterized by a high hereditary susceptibility to CVB3-
induced cardiomyopathy (6, 15, 41). Upon viral infection of
cardiomyocytes, heart tissue injury during the first days is
mainly attributed to direct virus-induced cytotoxicity, while
the activation of local type I interferon responses (T1IFN)
is substantially hampered in this strain (7, 8). This phase of
ongoing viral replication is accompanied and succeeded by
the recruitment of cells of the innate immune response such
as NK cells and monocytes (42). Later on, infiltration with
immune cells of the adaptive immune response such as T and
B cells follows (15). Analysis of the composition of leukocytes
in the heart revealed that 8 days after viral infection a general
reduction in invading immune cells was observed which suggests
that hampering early responders, such as monocytes e.g., by
reduced production of lymphocyte-attracting chemokines might
dampen the infiltration and activation of subsequent populations
as well. Although we found an overall reduction of CD4+ T
cells in the heart in siCSF-1 treated mice, we cannot conclude
on the influence of silencing the CSF-1 axis on CD4+ T cell
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FIGURE 6 | CSF-1 silencing during EAM diminishes infiltration of inflammatory monocytes into injured mouse hearts. (A) EAM was induced by inoculation of myosin
peptide in conjunction with Freud’s adjuvant and mice were boosted after 7 days. Nanoparticle-encapsulated CSF-1 siRNA #7 (Figure 3) was investigated regarding
(Continued)
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FIGURE 6 | to its potential to manipulate EAM in comparison to siLUC (control). Therefore, mice were treated with 0.5 mg/kg siRNA intravenously every other day
starting 14 days after EAM induction, and mice were sacrificed 21 days after the first immunization. (B) Representative dot plots (left) and enumeration (right) of
inflammatory Ly6Chi monocytes in heart tissue of siLUC- and siCSF-1-treated mice (n = 8). (C) Representative dot plots (left) and quantification of
granulocyte-monocyte progenitors (GMPs) (right) found in bone marrow of siLUC- and siCSF-1-treated mice during EAM (n = 12). (D) Representative FACS plots (left)
and quantification (right) of BrdU incorporation in GMPs of the bone marrow in siLUC- and siCSF-1 treated mice (n = 8). (E) Representative FACS density plots (left)
and quantification of monocytes/macrophages (right) in the blood of siLUC- and siCSF-1- treated mice (n = 7). Unpaired t-tests were used. p-values are indicated on
the graph and significant differences (p < 0.05) are marked with blue color.
FIGURE 7 | siRNA-mediated knockdown of CSF-1 during acute EAM attenuates the development of chronic disease states. (A) EAM induction and siRNA treatment
was conducted as shown in A. Mice were sacrificed after 30 days. (B) Representative Masson’s trichrome stains of heart tissue sections obtained 30 days after EAM
induction are depicted (left: scale bar = 150 nm). Fibrosis was scored microscopically (n = 8 for siLUC and siCSF-1 as well as n = 7 for siCSF-1R). (C) Heart function
was evaluated 30 days after the initial immunization by echocardiography. Representative M-mode echocardiographic images are shown during late state EAM.
Calculated left ventricular ejection fraction (EF) (n = 8 for siLUC and siCSF-1 as well as n = 7 for siCSF-1) is shown. One-way-ANOVA was performed. Since ANOVA
was significant, a Sidak-Holm-multiple comparison was performed. p-values of multiple comparison are indicated. Blue color indicates p < 0.05.
differentiation e.g., into regulatory T cells or Th1 and Th17
cells. From our data we cannot conclude on possible additional
effects e.g., of regulatory CD4+ T cells that are known to mitigate
the inflammatory tissue damage in the heart (43, 44). CSF-1
facilitates myeloid cell differentiation, monocyte survival, and
macrophage proliferation. It was recently shown that CSF-1R
also plays a role in splenic monocytopoiesis (33). Monocytes
are also important producers of CSF-1 themselves. Hume and
MacDonald suggested that modulation of the CSF-1 axis may
be beneficial under pathological conditions (45). We here show
that siRNA-mediated knockdown of CSF-1 in monocytes and
its imminent precursors leads to a significant reduction of
inflammatory Ly6Chi monocyte numbers in the inflamed heart.
We speculate that this observation results from arresting the CSF-
1-dependent monocyte/myeloid cell development at precursor
stages. This hypothesis is supported by detection of increased
GMP cell numbers in the bone marrow in siCSF-1-treated
animals during EAM. Although increased cell numbers may also
arise from increased proliferation rates, this situation seems to
be unlikely, since the percentages of proliferating GMPs in the
bone marrow of siCSF-1- and siLUC-treated animals did not
differ. Consistently, the numbers of myeloid cells were reduced
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FIGURE 8 | Graphical synopsis: The CSF-1 axis is induced in patients with acute myocarditis. Based on the preponderant role of CSF-1 for monocyte
differentiation/maturation and the disease-modifying function of monocytes during the course of inflammatory heart disease, we investigated how silencing of CSF-1
in monocytes/macrophages using nanoparticle encapsulated siRNA influences heart tissue damage during the onset of acute viral myocarditis and upon
manifestation of acute inflammation in an autoimmune myocarditis model. Silencing of the myeloid CSF-1 axis was beneficial for preventing inflammatory tissue
damage in the heart and preserving cardiac function at acute and chronic disease states without compromising innate immunity’s critical defense mechanisms.
in the blood stream of siCSF-1-treated animals during EAM.
In agreement with this and the fact that other than in siLUC-
treated mice enhanced monocyte counts were not observed
in the blood in siCSF-1-treated mice during AVM (data not
shown), we found a reduction of CSF-1R abundance in the
spleen during AVM in the siCSF-1 group. The spleen itself is
a source for monocytes with local production and from which
they are recruited to the site of inflammation (34). CSF-1R
is expressed throughout the mononuclear phagocyte system,
which is primarily composed of monocytes and macrophages
(22, 46). A reduction of CSF-1R expression might also be
indicative for reduced numbers of monocytes and macrophages.
These findings further underscore our assumption of a halted
monocyte/macrophage production due to CSF-1 knockdown
during inflammation. Mice that carry a deleterious mutation in
CSF-1 develop characteristic skeletal malformation, caused by
defective osteoclasts. In the context of an inflammatory disease,
such as atherosclerosis however, deletion of CSF-1 results in
dramatically reduced atherosclerotic plaque size (47, 48). After
myocardial infarction an upregulation of CSF-1 is observed in
ischemic areas for more than 5 days after the injury (49). In
this context, CSF-1 also appears to exhibit indirect effects by
regulating chemokine production (49). In the absence of CSF-
1, GM-CSF controls the differentiation of selected macrophage
subsets and may lead to an enhancement of macrophage lineage
numbers (50). Under certain conditions, GM-CSF induces an
inflammatory program marked by increased IL-1, IL-6 and
TNF-α secretion, whereas the presence of CSF-1 suppresses
the production of pro-inflammatory signals (51). Others have
reported that administration of CSF-1 in EAM between days
21 and 29 after disease induction ameliorated cardiac fibrosis
and left ventricular dysfunction by preventing the accumulation
of fibroblasts (52). Notably, no effects were observed in the
above mentioned study when CSF-1 was administered at later
stages. These conflicting results stress the importance of timing
in CSF-1 modulation. The reduced numbers of inflammatory
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monocytes due to silencing myeloid CSF-1 from days 14 to 21
observed in this study may outweigh the beneficial effects of
CSF-1 in the inflamed heart at these early stages. In addition,
macrophages have been shown to release pro-fibrotic cytokines
such as TGF-β, which causes the differentiation of fibroblasts
to myofibroblasts and a massive deposition of extracellular
matrix proteins such as collagens (53). Since we see a reduction
of myeloid cells during myocarditis in response to siCSF-
1 treatment and this includes macrophages, we propose that
thereby achieved reduction of pro-fibrotic signals most likely
contributes to lower scar formation as observed at advanced
states of EAM.
It has been reported that other cell types beyond cells of
the myeloid lineage are capable of CSF-1 expression under
inflammatory conditions, including fibroblasts and endothelial
cells (54, 55). These cells may also influence monocyte
production/proliferation during myocarditis. Nevertheless, at
the acute state of virus-mediated myocarditis, we observed
that Mac-3 positive cells like monocytes/macrophages, which
infiltrate the heart, may represent the main producers of CSF-
1. Many studies using different pathogenic models of bacterial,
viral and fungal infections have highlighted the importance
and requirement of TNF- and NO-producing monocytes as
facilitators of the resolution of an infection (56). Also, during
inflammation bone-marrow derived monocytes can mature
into macrophages (56) and macrophage-depletion results in
increased virus titers in infected mouse hearts (17). Therefore,
it was somewhat surprising at the first glance that depletion
of monocytes upon siCSF-1 treatment actually improved virus-
mediated pathology. We found no experimental evidence that
virus dissemination, control and elimination had been adversely
affected by such immune-modulating intervention. Since virus
titers were not significantly influenced by siCSF-1-treatment, the
impressively reduced inflammatory injury and preserved cardiac
function in this group is not influenced by direct virus-mediated
effects. These data suggest that virus-induced inflammation can
be segregated from pathways that promote and limit virus
infection and CSF-1-induced monocyte maturation. Monocytes
can be directly activated by CVB3 infection resulting in the
production of pro-inflammatory cytokines (57). Thereby, these
cells can contribute to a strong inflammatory response and
eventual tissue damage in themyocardium. Further experimental
evidence for an adverse function of myeloid immune cells
comes from macrophage depletion studies, where myocardial
injury and formation of cardiac fibrosis were substantially
diminished despite and in clear contrast to increased viral
burden during AVM (17). Interestingly and in line with
our findings in siCSF-1 treated A.BY/SnJ mice, macrophage
depletion did not adversely affect clearance of infectious virus
particles (17). We conclude that attenuated innate immune
cell mobilization and hampered CSF-1-driven differentiation of
innate myeloid cells in siCSF-1-treated mice directly suppresses
cytotoxicity induced by cytokine production and/or infiltration
with lymphocytes in viral myocarditis. Although there is a clear
causal relationship between T1IFN-mediated suppression of viral
load in infected cardiac cells and attenuation of inflammation
and chronic tissue damage (8, 32), several publications including
work of our group support the concept that—independent
of direct virus-induced cell injury—particularly monocytes
and macrophages are important players in inflammation and
chronic organ damage in response to Coxsackievirus infection
(4, 14, 58, 59).
Taken together, modulation of the CSF-1 axis in the myeloid
cell lineage with siRNAs at early stages has beneficial acute and
long-term effects in both viral and autoimmune myocarditis.
Our data support the notion that particularly infiltrating myeloid
cells contribute to acute and chronic functional impairment
in inflammatory heart disease. Since pathogen control was not
influenced upon suppression of the CSF-1 axis in myeloid
cells, this study yields important insights for translating the
pathophysiological role of CSF-1 from animal models to putative
novel therapeutic targets for patients with inflammatory heart
disease.
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